Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care

Utilizing a Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care

This clinical trial studies the effectiveness of a newly developed survivorship mobile application (app) designed for survivors, or their caregivers, of childhood cancer to help them better navigate long-term follow-up care. The survivorship app provides survivors access to their treatment history and follow-up recommendations, improves knowledge of their diagnosis, treatment, risks, and recommended follow-up care by using a message notification. The ability to quickly connect and establish care planning may enhance adherence to recommended follow-up.

Study Overview

• Status: Recruiting
• Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Childhood Cancer
• Intervention / Treatment: Behavioral: Survivorship mobile application; Other: Questionnaires

Detailed Description

PRIMARY OBJECTIVE:

I. To determine the difference in survivor/caregiver knowledge and understanding of diagnosis, treatment information, and follow-up needs using the survivorship app.

SECONDARY OBJECTIVE:

I. To validate the usability and effectiveness of the survivorship mobile application.

OUTLINE:

Participants are seen in the survivorship clinic and receive education about potential late effects and the survivorship application on study. Participants then use the survivorship app for 4 months on study.

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Patricia Murphy, RN; Phone Number: (415) 476-2700; Email: Patricia.Murphy@ucsf.edu

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94143
      • Recruiting
      • University of California, San Francisco
      • Principal Investigator: Robert Goldsby, MD
      • Contact: Patricia Murphy, RN; Phone Number: 415-476-2700; Email: Patricia.Murphy@ucsf.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Survivors of childhood cancer attending Survivorship Clinic at University of California, San Francisco (UCSF) OR caregivers of a childhood cancer survivor attending Survivorship Clinic at UCSF.
• Must have a mobile device (smartphone or smart-tablet) with service plan.
• Must have ability to read, write, and understand English language.

Exclusion Criteria:

• An individual who does not meet any of the criteria mentioned above will be excluded from participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Survivorship Mobile Application; Participants are seen in the survivorship clinic and receive education about potential late effects and the survivorship application on study. Participants enrolled in this study will be asked to complete two self-administered questionnaires at 4 time points. Questionnaires will be designed and made available electronically, to be completed on the participant's personal mobile device (e.g., mobile phone).

Behavioral: Survivorship mobile application; Mobile phone application; Other Names: Survivorship App; Other: Questionnaires; Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in knowledge questionnaire score	The knowledge of the participant will be measured using a 12-item questionnaire that assesses the awareness of their treatment and health issues in four categories: (1) diagnosis, (2) treatment, (3) risks, and (4) recommended follow-up. A scoring system has been devised which will give a score to each questionnaire out of 100 possible points. The change in participants knowledge scores >=20 points from baseline will be reported.	Up to 4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
System usability scale (SUS) score > 68	System Usability Scale (SUS) consists of a 10-item survey with five response options from Strongly agree to Strongly disagree. The scoring of positive questions is done as follows: The user's score is reduced by one point. For example, if the user's score is 4 for question 5, then the outcome score will be 3. The scoring of negative questions is done as follows: The user's score is subtracted from 5. For example, if the user's score is 3 for question 4, then the new score will be 2. After all the scores are determined, the sum of the scores is multiplied by 2.5 to make the range between 0 and 100. Scores above 68 are considered above average. The proportion of participants with an acceptable usability score > 68 will be reported.	Up to 2 months

Collaborators and Investigators

• Sponsor: University of California, San Francisco
• Collaborators: Swim Across America
• Investigators: Principal Investigator: Robert Goldsby, MD, University of California, San Francisco

Study record dates

Study Major Dates

• Study Start (Actual): November 29, 2022
• Primary Completion (Estimated): April 30, 2026
• Study Completion (Estimated): April 30, 2026

Study Registration Dates

• First Submitted: November 29, 2022
• First Submitted That Met QC Criteria: November 29, 2022
• First Posted (Actual): December 8, 2022

Study Record Updates

• Last Update Posted (Actual): July 23, 2025
• Last Update Submitted That Met QC Criteria: July 21, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: 220813; NCI-2022-09452 (Registry Identifier: NCI Clinical Trials Reporting Program (CTRP))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No